Abstract
An animal model of myasthenia gravis (MG), termed experimental autoimmune MG (EAMG), can be induced in C57BL/6 (B6, H-2 b ) mice by immunization with Torpedo californica acetylcholine receptor ( t AChR). We have investigated the effect of vaccination with MHC class II peptide I-A g b 62-76 on clinical EAMG and on T cell and antibody (Ab) responses against t AChR. B6 mice were vaccinated with the peptide (25 w g/mouse) four times prior to two injections with t AChR. The incidence of clinical EAMG in vaccinated mice was 14% (3 out of 22 mice) compared to 48% (17 out of 35 mice) in control non-vaccinated or PBS-immunized mice. The T cells of the vaccinated group showed lower proliferative responses to t AChR and to T-cell epitope-containing t AChR f -chain peptides than the T cells of controls. In addition, the Ab responses in the vaccinated group was also lower against t AChR and some of the B-cell epitope-containing t AChR f -chain peptides.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
